Ethics and Transparency

CODE OF CONDUCT

The Code of Conduct expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical nature.

The application of the following principles is guaranteed by the existence of procedures within the Group aimed at ensuring that its employees, internal bodies and third parties acting on its behalf, operate effectively in accordance with ethical principles.

This version of the Code of Conduct has been approved by the Board of Directors of Chiesi Farmaceutici S.p.A.. This constitutes an official Group document and as such is binding upon all the bodies, employees, consultants, collaborators, agents and, at a more general level all third parties acting on behalf of the Group.

In order to uphold the high ethical and legal standards of the Group, since 2015 Chiesi also adopted an Anti-Bribery Policy. The purpose of this Policy is to provide Chiesi people and business partners with a series of general principles on how to recognise and deal with situations involving bribery and how to comply with related laws and regulations, which are in line with the provisions set out in Chiesi’s Code of Conduct.

Code of Conduct

Chiesi Anti-Bribery Policy 2023

Code of Interdependence

EFPIA

As a member of EFPIA (European Federation of Pharmaceutical Industries and Associations) Chiesi is fostering the transparency on the interaction between the pharmaceutical industry and health care professionals & organisations according EFPIA, as well as all national legal regulations, as we are convinced to be independent partners with the same goal: cooperation and exchange of knowledge, as well as research and development without tortious interference or influence.

Disclosure DATA from 2016 onwards

INDIVIDUAL DISCLOSURE

Donations and grants to HCO, HCP’s organisations and associations, organisations providing healthcare;
Costs related to Events: registration fees, sponsorship agreements, travel and accommodation;
Fees for Service and Consultancy to HCPs and HCOs: fees and related expenses must be disclosed separately. This is only applicable, when the HCPs or HCOs have provided their consent on the individual disclosure, otherwise the data needs to be published in the aggregated disclosure data.

AGGREGATE DISCLOSURE

R&D costs: including costs for related events (investigators’ meetings, etc);
Transfers of value which cannot be disclosed on an individual basis for legal reasons

For further information regarding transparency please click here Transparenz | PHARMIG

For more questions on the EFPIA or PHARMIG transparency codes or concerning a disclaimer or revocation of your conset to the individual disclosure, please do not hesitate to contact us ( compliance.CEE(at)chiesi.com ) or our affiliates.

The revocation of your consent to the publication of the data shoul be adresses to anfrage.at[at]chiesi.com.